| Similar Articles |
|---|
 |
The Motley Fool
December 4, 2006
Brian Lawler |
I Think Axcan, I Think Axcan This small pharma is quietly growing earnings. If it can continue to keep its spending under control, investors will continue to be rewarded.   |
The Motley Fool
April 5, 2011
Frank Vinluan |
Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. |
The Motley Fool
December 4, 2007
Brian Lawler |
Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Axcan's Got Guts While growth for this Canadian drug company is a bit sluggish, ITAX could be a major winner. Investors looking at Axcan shares should treat this stock like a hybrid biotech stock. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
April 5, 2010
Brian Orelli |
Up 30%? What Are You People On? Fast-track designations aren't worth much more than the paper they're printed on. |
The Motley Fool
November 27, 2006
Brian Lawler |
Pharmaxis Gets Good News From the FDA Fast-track designation gives this pharmaceutical stock a bump. |
The Motley Fool
November 11, 2005
Stephen D. Simpson |
Axcan Not in the Ash Can The base business of this Canadian specialty pharmaceutical won't grow quickly, but cash flow and the potential of the new ITAX drug could still move the shares. |
The Motley Fool
November 3, 2009
Brian Orelli |
A Little Distracted, Are You, Merck? The FDA rejects its latest application. |
The Motley Fool
February 22, 2006
Stephen D. Simpson |
Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
